Using a Single Dose of Dexamethasone at 0.6 Versus 0.15 mg/kg of Body Weight for the Treatment of Croup

Objective: To compare the effectiveness and adverse events associated with treating children with croup with dexamethasone at 0.15 versus 0.6 mg/kg body weight. Methods: This retrospective cohort study included children (younger than 18 y) with a clinical diagnosis of croup in 4 pediatric emergency departments (EDs) between January 2017 and December 2019. The primary outcome was return visit to the ED for croup within 7 days, and the secondary outcomes were hospitalization within 7 days and occurrence of adverse events within 30 days. Both χ 2 tests and logistic regression models were used to compare differences in the proportions of children with ED return visits, hospitalizations, and adverse events associated with dose. Results: We included 14,205 children in the final analysis. Of the 13,437 croup episodes from children treated with dexamethasone at 0.15 mg/kg (n=172) or 0.6 mg/kg (n=13,265), 2.9% and 4.1%, respectively, were ED return visits within 7 days following treatment. The difference in the proportion of ED return visits following treatment with the 2 doses was not statistically significant (1.2%; 95% CI: −1.31 to 3.76). In a multivariable-adjusted model, 0.15 mg/kg was not associated with ED return visits within 7 days [adjusted odds ratio (aOR)=0.88; 95% CI: 0.31-1.97], but was associated with hospitalization (aOR=3.18; 95% CI: 1.52-6.00). A total of 135 (1%) of all croup episodes had at least 1 adverse event within 30 days. Of those treated with 0.15 or 0.6 mg/kg, 1.2% and 1%, respectively, had at least 1 adverse event within 30 days. The most common adverse event was pneumonia (0.8%). Conclusions: Our findings suggest that low-dose dexamethasone, 0.15 mg/kg, may be as effective as 0.6 mg/kg with comparable proportions of ED return visits and adverse events within 7 days. However, low-dose dexamethasone was associated with increased hospitalization. Clinicians should weigh the potential risk of hospitalization when choosing 0.15 mg/kg of dexamethasone.

Authors

Institutions

Publication Details

Journal
Pediatric Emergency Care
Published
2026-10-16
DOI
https://doi.org/10.1097/pec.0000000000003738
Primary Topic
Otolaryngology and Infectious Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Using a Single Dose of Dexamethasone at 0.6 Versus 0.15 mg/kg of Body Weight for the Treatment of Croup

Amy Catherine Plint, Terry Paul Klassen, Jennifer Turnbull, D. Johnson et al.
Pediatric Emergency Care
Otolaryngology and Infectious Diseases
article

Using a Single Dose of Dexamethasone at 0.6 Versus 0.15 mg/kg of Body Weight for the Treatment of Croup

Amy Catherine Plint, Terry Paul Klassen, Jennifer Turnbull, D. Johnson, Alex Aregbesola, Robert F Balshaw, Banke Oketola, Apoorva Gangwani, Hoda Badran
article en

Abstract

Objective: To compare the effectiveness and adverse events associated with treating children with croup with dexamethasone at 0.15 versus 0.6 mg/kg body weight. Methods: This retrospective cohort study included children (younger than 18 y) with a clinical diagnosis of croup in 4 pediatric emergency departments (EDs) between January 2017 and December 2019. The primary outcome was return visit to the ED for croup within 7 days, and the secondary outcomes were hospitalization within 7 days and occurrence of adverse events within 30 days. Both χ 2 tests and logistic regression models were used to compare differences in the proportions of children with ED return visits, hospitalizations, and adverse events associated with dose. Results: We included 14,205 children in the final analysis. Of the 13,437 croup episodes from children treated with dexamethasone at 0.15 mg/kg (n=172) or 0.6 mg/kg (n=13,265), 2.9% and 4.1%, respectively, were ED return visits within 7 days following treatment. The difference in the proportion of ED return visits following treatment with the 2 doses was not statistically significant (1.2%; 95% CI: −1.31 to 3.76). In a multivariable-adjusted model, 0.15 mg/kg was not associated with ED return visits within 7 days [adjusted odds ratio (aOR)=0.88; 95% CI: 0.31-1.97], but was associated with hospitalization (aOR=3.18; 95% CI: 1.52-6.00). A total of 135 (1%) of all croup episodes had at least 1 adverse event within 30 days. Of those treated with 0.15 or 0.6 mg/kg, 1.2% and 1%, respectively, had at least 1 adverse event within 30 days. The most common adverse event was pneumonia (0.8%). Conclusions: Our findings suggest that low-dose dexamethasone, 0.15 mg/kg, may be as effective as 0.6 mg/kg with comparable proportions of ED return visits and adverse events within 7 days. However, low-dose dexamethasone was associated with increased hospitalization. Clinicians should weigh the potential risk of hospitalization when choosing 0.15 mg/kg of dexamethasone.

Pediatric Emergency Care
University of Ottawa (CA), University of Calgary (CA), Saskatchewan Health Authority (CA), Children's Hospital of Eastern Ontario (CA), Saskatchewan Health (CA), McGill University Health Centre (CA), Alberta Children's Hospital (CA), Children's Hospital Research Institute of Manitoba (CA), George & Fay Yee Centre for Healthcare Innovation (CA), University of Manitoba (CA), McGill University (CA)
Research Manitoba
Good health and well-being
Openalex Percentile: Top 12%
Otolaryngology and Infectious Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.